乳腺癌新辅助化疗的研究现状

被引：18

作者：

马文玥

张频

机构：

[1] 中国医学科学院北京协和医学院肿瘤医院内科

来源：

癌症进展 | 2011年 / 9卷 / 02期

关键词：

乳腺癌; 新辅助化疗;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

摘要：

<正>乳腺癌是妇女最常见的恶性肿瘤之一,部分患者初诊时已处于局部晚期,新辅助化疗应运而生,并且由于其独特优势,成为目前乳腺癌治疗中的热点。本文就新辅助化疗适应证、化疗方案选择、疗效预测等方面的问题及研究现状综述如下。

引用

页码：165 / 171

页数：7

共 11 条

[1] Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis [J].

Nishimura, Reiki ;

Osako, Tomofumi ;

Okumura, Yasuhiro ;

Hayashi, Mitsuhiro ;

Arima, Nobuyuki .

BREAST CANCER, 2010, 17 (04) :269-275

[2] Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages II and III breast cancer [J].

Han, Sehwan ;

Kim, Jeryong ;

Lee, Jinsun ;

Chang, Eilsung ;

Gwak, Geumhee ;

Cho, Hyunjin ;

Yang, Keun Ho ;

Park, Sungjin ;

Park, Kyeongmee .

EJSO, 2009, 35 (06) :583-587

[3]

Changes in biological markers, particularly hormone receptors, due to pre-operative chemotherapy (epirubicin/docetaxel) in operable breast cancer[J] . Rumiko Tashima,Reiki Nishimura.Oncology Reviews . 2008 (4)

[4] Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients [J].

Byrski, T. ;

Huzarski, T. ;

Dent, R. ;

Gronwald, J. ;

Zuziak, D. ;

Cybulski, C. ;

Kladny, J. ;

Gorski, B. ;

Lubinski, J. ;

Narod, S. A. .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) :359-363

[5] Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy [J].

Vargas-Roig, Laura M. ;

Cuello-Carrion, F. Dario ;

Fernandez-Escobar, Nicolas ;

Daguerre, Pedro ;

Leuzzi, Marcela ;

Ibarra, Jorge ;

Gago, Francisco E. ;

Nadin, Silvina B. ;

Ciocca, Daniel R. .

MOLECULAR ONCOLOGY, 2008, 2 (01) :102-111

[6] Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer [J].

Penault-Llorca, Frederique ;

Abrial, Catherine ;

Raoelfils, Ines ;

Cayre, Anne ;

Mouret-Reynier, Marie-Ange ;

Leheurteur, Marianne ;

Durando, Xavier ;

Achard, Jean-Louis ;

Gimbergues, Pierre ;

Chollet, Philippe .

HUMAN PATHOLOGY, 2008, 39 (08) :1221-1228

[7] HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer [J].

Andre, Fabrice ;

Mazouni, Chafika ;

Liedtke, Cornelia ;

Kau, Shu-Wan ;

Frye, Debby ;

Green, Marjorie ;

Gonzalez-Angulo, Ana M. ;

Symmans, W. Fraser ;

Hortobagyi, Gabriel N. ;

Pusztai, Lajos .

BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (02) :183-190

[8]

Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel[J] . Rosalba Torrisi,Alessandra Balduzzi,Raffaella Ghisini,Andrea Rocca,Luca Bottiglieri,Filippo Giovanardi,Paolo Veronesi,Alberto Luini,Laura Orlando,Giuseppe Viale,Aron Goldhirsch,Marco Colleoni.Cancer Chemotherapy and Pharmacology . 2008 (4)

[9] Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer [J].

Pusztai, L ;

Krishnamurti, S ;

Cardona, JP ;

Sneige, N ;

Esteva, FJ ;

Volchenok, M ;

Breitenfelder, P ;

Kau, SW ;

Takayama, S ;

Krajewski, S ;

Reed, JC ;

Bast, RC ;

Hortobagyi, GN .

CANCER INVESTIGATION, 2004, 22 (02) :248-256

[10]

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival[J] . Keith N Ogston,Iain D Miller,Simon Payne,Andrew W Hutcheon,Tarun K Sarkar,Ian Smith,A Schofield,Steven D Heys.The Breast . 2003 (5)

← 1 2 →